The prospect of targeting inflammation to treat residual cardiovascular risk using the monoclonal antibody canakinumab (Ilaris) appears to be slim to none in the wake of recent decisions from ...
We analysed the past 20 years of drug project history with the aim of understanding more about how the pharmaceutical industry has been performing with regard to therapeutic mechanisms and their ...
Sally Engle Merry receives funding from the US National Science Foundation.. Benedict Kingsbury receives funding from the US National Science Foundation Kevin E. Davis receives funding from US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results